Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17257469 | CHIMERIC RECEPTORS IN COMBINATION WITH TRANS METABOLISM MOLECULES ENHANCING GLUCOSE IMPORT AND THERAPEUTIC USES THEREOF | December 2020 | January 2025 | Abandon | 48 | 3 | 2 | No | No |
| 17051341 | OCA-B PEPTIDE CONJUGATES AND METHODS OF TREATMENT | October 2020 | July 2024 | Allow | 45 | 2 | 0 | Yes | No |
| 17063505 | TREATMENT OF VIRAL INFECTION | October 2020 | March 2025 | Abandon | 53 | 1 | 0 | No | No |
| 17028608 | Payload-Polymer-Protein Conjugates | September 2020 | February 2025 | Abandon | 53 | 2 | 1 | No | No |
| 17025732 | METHODS FOR IMPROVING THE EFFICACY AND EXPANSION OF IMMUNE CELLS | September 2020 | October 2024 | Allow | 49 | 2 | 1 | Yes | Yes |
| 16975725 | Treatment and prevention of pre-eclampsia | August 2020 | October 2024 | Abandon | 50 | 1 | 0 | No | No |
| 16969381 | CHIMERIC ANTIGEN RECEPTOR THERAPY IN COMBINATION WITH IL-15R AND IL15 | August 2020 | October 2024 | Abandon | 50 | 4 | 1 | No | No |
| 16849023 | PROCESS FOR GENERATING GENETICALLY ENGINEERED AUTOLOGOUS T CELLS | April 2020 | October 2024 | Allow | 54 | 6 | 1 | Yes | No |
| 16652948 | METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION | April 2020 | November 2024 | Allow | 55 | 4 | 1 | No | No |
| 16617101 | DTERT VACCINES AND METHODS OF TREATMENT USING THE SAME | November 2019 | April 2025 | Abandon | 60 | 5 | 0 | No | Yes |
| 16591323 | Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers | October 2019 | January 2020 | Allow | 4 | 1 | 0 | No | No |
| 16443219 | EFFECTIVE GENERATION OF TUMOR-TARGETED T CELLS DERIVED FROM PLURIPOTENT STEM CELLS | June 2019 | December 2024 | Abandon | 60 | 4 | 1 | No | Yes |
| 16340376 | MODULATION OF NOVEL IMMUNE CHECKPOINT TARGETS | April 2019 | June 2025 | Allow | 60 | 5 | 1 | Yes | No |
| 16317766 | HDAC INHIBITORS FOR USE WITH NK CELL BASED THERAPIES | January 2019 | May 2025 | Allow | 60 | 6 | 1 | Yes | Yes |
| 16146300 | DIAGNOSTIC, PROGNOSTIC, AND MONITORING METHODS FOR CHRONIC LYMPHOCYTIC LEUKEMIA | September 2018 | August 2024 | Allow | 60 | 6 | 0 | No | No |
| 16021777 | Functional Antibody Fragment Complementation for a Two-Components System for Redirected Killing of Unwanted Cells | June 2018 | May 2022 | Abandon | 47 | 7 | 1 | Yes | No |
| 15688021 | Androgen Suppression, Prostate-Specific Membrane Antigen and the Concept of Conditionally Enhanced Vulnerability | August 2017 | November 2024 | Abandon | 60 | 6 | 0 | No | Yes |
| 15548340 | A CHIMERIC ANTIGEN RECEPTOR SIGNALLING SYSTEM COMPRISING HETERODIMERIZATION DOMAINS | August 2017 | October 2019 | Allow | 27 | 2 | 1 | Yes | No |
| 15301148 | CHIMERIC ANTIGEN RECEPTOR (CAR) SIGNALLING SYSTEM | September 2016 | October 2019 | Allow | 36 | 3 | 1 | Yes | No |
| 15160742 | ANTIBODIES SPECIFIC FOR TROP-2 AND THEIR USES | May 2016 | June 2018 | Allow | 25 | 1 | 0 | No | No |
| 15038135 | OLFACTOMEDIN-4, NEUDESIN AND DESMOPLAKIN AS BIOMARKERS OF BREAST CANCER | May 2016 | June 2019 | Allow | 36 | 3 | 1 | Yes | No |
| 14888354 | MAB 2 ANTI-MET ANTIBODY | October 2015 | February 2018 | Allow | 27 | 1 | 1 | No | No |
| 14780652 | A CANCER VACCINE FOR DOGS | September 2015 | July 2018 | Allow | 33 | 2 | 1 | Yes | No |
| 14817063 | COMPOSITIONS AND METHODS FOR TREATING CONDITIONS RELATED TO EPHRIN SIGNALING WITH CUPREDOXINS AND MUTANTS THEREOF | August 2015 | April 2018 | Allow | 33 | 3 | 0 | No | No |
| 14655088 | Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy | June 2015 | March 2019 | Allow | 45 | 4 | 1 | No | No |
| 14738630 | MUTATIONS IN THE BCR-ABL TYROSINE KINASE ASSOCIATED WITH RESISTANCE TO STI-571 | June 2015 | January 2018 | Allow | 32 | 2 | 1 | No | No |
| 14438275 | METHODS FOR PREDICTING THE SENSITIVITY OF A SUBJECT TO IMMUNOTHERAPY | April 2015 | June 2017 | Allow | 26 | 2 | 1 | No | No |
| 14413416 | LY6K EPITOPE PEPTIDES FOR TH1 CELLS AND VACCINES CONTAINING THE SAME | January 2015 | February 2017 | Allow | 25 | 2 | 1 | No | No |
| 14567653 | CANCER DIAGNOSIS AND TREATMENT OF CANCER USING ANTI-ROBO 1 ANTIBODY | December 2014 | January 2017 | Allow | 25 | 2 | 0 | No | No |
| 14460871 | ANTIBODIES SPECIFIC FOR TROP-2 AND THEIR USES | August 2014 | April 2016 | Allow | 20 | 1 | 0 | Yes | No |
| 14124595 | HE4 Based Therapy For Malignant Disease | August 2014 | January 2018 | Allow | 49 | 3 | 1 | No | No |
| 14372972 | Combination Therapy for Cancer Using HSP27 Inhibitor and EGFR Tyrosine Kinase Inhibitors or Anti-Folates | July 2014 | June 2017 | Allow | 35 | 4 | 0 | Yes | No |
| 14310258 | METHOD OF TREATMENT OF CANCER USING GUANOSINE 3', 5' CYCLIC MONOPHOSPHATE (CYCLIC GMP) | June 2014 | August 2017 | Allow | 38 | 4 | 0 | Yes | No |
| 14276713 | SOLUBLE CD27 (SCD27) AND THE USE THEREOF | May 2014 | March 2017 | Allow | 34 | 4 | 1 | Yes | No |
| 14252418 | METHOD FOR TREATING BRAIN CANCER USING A NOVEL TUMOR SUPPRESSOR GENE AND SECRETED FACTOR | April 2014 | June 2016 | Allow | 26 | 2 | 0 | Yes | Yes |
| 14348365 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING CANCER | March 2014 | March 2016 | Allow | 23 | 2 | 1 | Yes | No |
| 14240798 | PROTEIN INVOLVED IN DETECTION OF CANCER METASTASIS AND A TREATMENT THEREOF | February 2014 | February 2016 | Allow | 23 | 2 | 1 | Yes | No |
| 14162487 | GENES AND POLYPEPTIDES RELATING TO BREAST CANCERS | January 2014 | July 2015 | Allow | 18 | 1 | 0 | No | No |
| 14125155 | METHOD FOR PREDICTING THE RESPONSE TO TREATMENT WITH AN HER2-BLOCKING AGENT | December 2013 | September 2016 | Allow | 33 | 4 | 0 | No | No |
| 14117806 | USE OF ANTI-CD19 MAYTANSINOID IMMUNOCONJUGATE ANTIBODY FOR THE TREATMENT OF B-CELL MALIGNANCIES SYMPTOMS | November 2013 | October 2016 | Allow | 35 | 2 | 1 | Yes | No |
| 14057596 | GUANYLYLCYCLASE C LIGANDS | October 2013 | May 2016 | Allow | 31 | 2 | 1 | Yes | No |
| 13988968 | PHARMACEUTICAL COMPOSITION | September 2013 | August 2015 | Allow | 27 | 2 | 0 | Yes | No |
| 13933555 | Methods and Compositions for Modulating T Cell and/or B Cell Activation | July 2013 | November 2015 | Allow | 29 | 2 | 0 | No | No |
| 13737349 | GENE RELATING TO ESTIMATION OF POSTOPERATIVE PROGNOSIS FOR BREAST CANCER | January 2013 | February 2016 | Allow | 37 | 3 | 0 | Yes | No |
| 13582931 | METHOD AND KIT FOR ISOLATING TARGET CELL | November 2012 | May 2014 | Allow | 20 | 1 | 1 | No | No |
| 13670730 | ANTIBODIES SPECIFIC FOR TROP-2 AND THEIR USES | November 2012 | May 2014 | Allow | 18 | 1 | 1 | Yes | No |
| 13641610 | Cancer-Related Glycopeptide Epitopes, Antibodies And Methods Of Use | October 2012 | January 2016 | Allow | 39 | 5 | 1 | No | No |
| 13553061 | MUC1 BASED GLYCOLIPOPEPTIDE VACCINE WITH ADJUVANT | July 2012 | October 2012 | Allow | 3 | 1 | 0 | Yes | No |
| 13547954 | MUTATIONS IN THE BCR-ABL TYROSINE KINASE ASSOCIATED WITH RESISTANCE TO STI-571 | July 2012 | May 2015 | Allow | 34 | 3 | 0 | No | No |
| 13422789 | COMPOSITIONS COMPRISING FUNGAL IMMUNOMODULATORY PROTEIN AND USE THEREOF | March 2012 | September 2013 | Allow | 18 | 1 | 0 | No | No |
| 13403679 | MUC1 Based Glycolipopeptide Vaccine with Adjuvant | February 2012 | August 2014 | Allow | 30 | 2 | 1 | Yes | No |
| 13314040 | METHODS FOR DETECTING AND INHIBITING ANGIOGENESIS | December 2011 | February 2013 | Allow | 14 | 1 | 0 | No | No |
| 13296620 | GENETIC PRODUCTS DIFFERENTIALLY EXPRESSED IN TUMORS AND THE USE THEREOF | November 2011 | July 2013 | Allow | 20 | 2 | 1 | No | No |
| 13294213 | Biological Markers Predictive Of Anti-Cancer Response To Insulin-like Growth Factor-1 Receptor Kinase Inhibitors | November 2011 | October 2012 | Allow | 12 | 1 | 0 | No | No |
| 13284341 | METHODS AND COMPOSITIONS FOR MODULATING T CELL AND/OR B CELL ACTIVATION | October 2011 | March 2013 | Allow | 17 | 1 | 1 | No | No |
| 13270482 | CYBP AS A MARKER FOR LUNG CANCER | October 2011 | November 2014 | Allow | 37 | 3 | 0 | Yes | No |
| 13126745 | ANTI-MUC1 ANTIBODY | September 2011 | February 2014 | Allow | 34 | 3 | 0 | Yes | No |
| 13200666 | Methods for assessing and identifying or evolving conditionally active therapeutic proteins | September 2011 | March 2017 | Allow | 60 | 6 | 1 | No | No |
| 13211090 | CANCEROUS DISEASE MODIFYING ANTIBODIES | August 2011 | May 2012 | Allow | 9 | 1 | 0 | No | No |
| 13182644 | PREVENTION AND TREATMENT OF PAIN USING ANTIBODIES TO LYSOPHOSPHATIDIC ACID | July 2011 | December 2015 | Allow | 53 | 4 | 0 | No | Yes |
| 13163951 | NEOEPITOPE DETECTION OF DISEASE USING PROTEIN ARRAYS | June 2011 | February 2014 | Allow | 32 | 2 | 1 | Yes | No |
| 13083205 | PSCA: PROSTATE STEM CELL ANTIGEN AND USES THEREOF | April 2011 | May 2013 | Allow | 25 | 2 | 0 | Yes | No |
| 12990557 | ANTI-HMGA1 MONOCLONAL ANTIBODIES, PROCESS FOR THEIR PREPARATION AND THEIR USE FOR THE QUANTITATIVE DETERMINATION OF HMGA1 | December 2010 | November 2012 | Allow | 25 | 1 | 2 | Yes | No |
| 12735274 | METHOD OF DETECTING LEUKEMIC CELL | October 2010 | August 2013 | Allow | 38 | 2 | 1 | Yes | No |
| 12870893 | THERAPEUTIC VACCINE TARGETED AGAINST P-GLYCOPROTEIN 170 FOR INHIBITING MULTIDRUG RESISTANCE IN THE TREATMENT OF CANCERS | August 2010 | November 2012 | Allow | 27 | 1 | 1 | Yes | No |
| 12869005 | Compositions and Methods for the Identification, Assessment, Prevention and Therapy of Thymic Lymphoma or Hamartomatous Tumours | August 2010 | December 2016 | Allow | 60 | 6 | 1 | Yes | No |
| 12824305 | NEOEPITOPE DETECTION OF DISEASE USING PROTEIN ARRAYS | July 2010 | August 2015 | Allow | 60 | 4 | 1 | Yes | No |
| 12816482 | METHODS FOR DIAGNOSING ORAL OR ORAL-PHARYNGEAL CANCER | June 2010 | April 2015 | Allow | 58 | 4 | 1 | No | No |
| 12377024 | GENES AND POLYPEPTIDES RELATING TO BREAST CANCERS | May 2010 | October 2013 | Allow | 57 | 2 | 1 | Yes | No |
| 12770472 | ANNEXIN A3 FOR CANCER DIAGNOSIS | April 2010 | January 2013 | Allow | 32 | 1 | 1 | Yes | No |
| 12730701 | OMENTUM AS A SOURCE OF STROMAL/STEM CELLS AND MEDICAL TREATMENTS USING STROMAL/STEM CELLS | March 2010 | January 2015 | Allow | 58 | 3 | 0 | No | No |
| 12677755 | CANCER DIAGNOSTIC KIT AND CANCER DIAGNOSTIC METHOD | March 2010 | January 2012 | Allow | 22 | 1 | 1 | Yes | No |
| 11990598 | USE OF AN ENDOPLASMIN FRAGMENT AND DERIVATIVES THEREOF AS BIOMARKER FOR COLORECTAL ADENOMA AND/OR CARCINOMA; METHOD FOR DETECTION AND TEST SYSTEM | January 2010 | August 2013 | Allow | 60 | 3 | 0 | Yes | No |
| 12615180 | METHOD FOR THE DIAGNOSIS OF CANCERS BY MEASURING THE CHANGES OF GLYCOSYLATION OF PROTEINS RELATED TO TUMORIGENESIS AND METASTASIS AND KIT FOR DIAGNOSIS OF CANCERS USING THE SAME | November 2009 | October 2011 | Allow | 23 | 1 | 0 | No | No |
| 12598746 | CANCER RELATED ISOFORMS OF COMPONENTS OF TRANSCRIPTION FACTOR COMPLEXES AS BIOMARKERS AND DRUG TARGETS | November 2009 | June 2012 | Allow | 32 | 6 | 1 | Yes | No |
| 12609483 | PCA3, PCA3 GENES, AND METHODS OF USE | October 2009 | June 2013 | Allow | 43 | 2 | 0 | No | No |
| 11920907 | COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF CHEMORESISTANT NEOPLASIA | October 2009 | March 2012 | Allow | 52 | 2 | 2 | Yes | No |
| 12605273 | DIRECTED ENGAGEMENT OF ACTIVATING FC RECEPTORS | October 2009 | October 2012 | Allow | 36 | 1 | 1 | Yes | No |
| 12541729 | PRO-ANGIOGENIC GENES IN OVARIAN TUMOR ENDOTHELIAL CELL ISOLATES | August 2009 | January 2013 | Allow | 41 | 3 | 1 | Yes | No |
| 12505620 | COMBINATION OF INTERCALATING ORGANOMETALLIC COMPLEXES AND TUMOR SEEKING BIOMOLECULES FOR DNA CLEAVAGE AND RADIOTHERAPY | July 2009 | February 2014 | Allow | 55 | 4 | 1 | No | No |
| 12299852 | TWO PORE CHANNELS AS REGULATORS OF PROLIFERATION IN CANCER | June 2009 | June 2012 | Allow | 44 | 2 | 1 | Yes | No |
| 12483774 | TRANSFERRIN RECEPTOR ANTIBODIES | June 2009 | January 2012 | Allow | 32 | 1 | 0 | Yes | No |
| 12480983 | A METHOD OF DETECTING COLORECTAL CANCER OF STAGES 0 TO I | June 2009 | April 2015 | Allow | 60 | 6 | 0 | No | No |
| 12480076 | GENE AND PROTEIN EXPRESSION PROFILES ASSOCIATED WITH THE THERAPEUTIC EFFICACY OF EGFR-TK INHIBITORS | June 2009 | October 2011 | Allow | 29 | 3 | 1 | Yes | No |
| 12464274 | PURIFIED SR-P70 PROTEIN | May 2009 | August 2010 | Allow | 15 | 1 | 0 | No | No |
| 12387457 | METHODS, ASSAYS AND KITS FOR CANCER DIAGNOSIS AND SCREENING UTILIZING GLYCAN-BINDING AND GLYCAN EPITOPES | May 2009 | June 2012 | Allow | 38 | 2 | 1 | Yes | No |
| 12423153 | GENETIC PRODUCTS DIFFERENTIALLY EXPRESSED IN TUMORS AND THE USE THEREOF | April 2009 | June 2013 | Allow | 50 | 6 | 1 | No | No |
| 12160766 | VACCINES AND IMMUNOTHERAPEUTICS USING CODON OPTIMIZED IL-15 AND METHODS FOR USING THE SAME | March 2009 | December 2011 | Allow | 41 | 1 | 1 | Yes | No |
| 12375179 | RECEPTOR-MEDIATED DELIVERY: COMPOSITIONS AND METHODS | January 2009 | April 2015 | Allow | 60 | 4 | 1 | Yes | No |
| 12373048 | POLYPEPTIDE, NUCLEIC ACID MOLECULE ENCODING IT AND THEIR USES | January 2009 | May 2012 | Allow | 41 | 4 | 1 | Yes | No |
| 11886886 | IDENTIFICATION OF BIOMARKERS BY SERUM PROTEIN PROFILING | December 2008 | December 2014 | Allow | 60 | 4 | 1 | Yes | No |
| 12303825 | MONOCLONAL ANTI-ANNEXIN A3 ANTIBODIES FOR THE DETECTION OF PROSTATE CARCINOMA | December 2008 | May 2011 | Allow | 29 | 2 | 1 | Yes | No |
| 12326997 | GENETIC PRODUCTS DIFFERENTIALLY EXPRESSED IN TUMORS AND THE USE THEREOF | December 2008 | August 2011 | Allow | 33 | 2 | 1 | No | No |
| 12158680 | METHOD FOR TREATING URINARY BLADDER CANCER | November 2008 | March 2011 | Allow | 33 | 1 | 1 | Yes | No |
| 12206670 | METHODS FOR IDENTIFYING MODULATORS OF APOPTOSIS | September 2008 | December 2010 | Allow | 27 | 1 | 0 | Yes | No |
| 12221019 | ANTI-CANCER PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING PATIENTS WITH CANCER | July 2008 | May 2012 | Allow | 45 | 2 | 1 | No | No |
| 12180794 | STABLE LYOPHILIZED PHARMACEUTICAL PREPARATIONS OF MONOCLONAL OR POLYCLONAL ANTIBODIES | July 2008 | February 2014 | Allow | 60 | 5 | 0 | No | No |
| 12172100 | DRUG SELECTION FOR LUNG CANCER THERAPY USING ANTIBODY-BASED ARRAYS | July 2008 | September 2015 | Allow | 60 | 5 | 1 | Yes | Yes |
| 12169561 | PSCA: PROSTATE STEM CELL ANTIGEN AND DISTINGUISHING ANDROGEN RECEPTOR NEGATIVE PROSTATE CANCER FROM BENIGN PROSTATIC HYPERPLASIA | July 2008 | February 2014 | Allow | 60 | 4 | 0 | No | No |
| 11911754 | ANTI-CANCER AGENT COMPRISING PROTEIN C INHIBITOR | May 2008 | September 2011 | Allow | 47 | 3 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner REDDIG, PETER J.
With a 50.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 19.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner REDDIG, PETER J works in Art Unit 1646 and has examined 163 patent applications in our dataset. With an allowance rate of 92.6%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 44 months.
Examiner REDDIG, PETER J's allowance rate of 92.6% places them in the 79% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by REDDIG, PETER J receive 2.96 office actions before reaching final disposition. This places the examiner in the 82% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by REDDIG, PETER J is 44 months. This places the examiner in the 15% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +8.7% benefit to allowance rate for applications examined by REDDIG, PETER J. This interview benefit is in the 40% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 24.5% of applications are subsequently allowed. This success rate is in the 39% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 54.3% of cases where such amendments are filed. This entry rate is in the 81% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
This examiner withdraws rejections or reopens prosecution in 88.2% of appeals filed. This is in the 81% percentile among all examiners. Of these withdrawals, 73.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 68.8% are granted (fully or in part). This grant rate is in the 74% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 22.1% of allowed cases (in the 98% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 17.2% of allowed cases (in the 94% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.